Stock Analiz

Lifevantage Corp LFVN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.97Market cap $63M
Open the interactive analysis →

Lifevantage Corp (LFVN) is a healthcare company listed in the US with a market value of about $63M. In the twelve months to September 30, 2026 it had revenue of $172M and net income of $3M, a net margin of 1.6%.

Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is future growth (1/5).

Key numbers: a P/E of 23.7, a price to free cash flow of 7.2, 5-year revenue growth of -4% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 23% below the current price.

About Lifevantage

Lifevantage is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $190M in 2015 to $183M in 2026, a decline of about 0.4% a year. It was profitable in 10 of the last 10 years in our data. It spends 1% of revenue on research and development.

Score: 3.0 / 5

Value3/5
Future growth1/5
Track record2/5
Financial health5/5
Shareholder returns4/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • 3-year free cash flow growth above 10% a year
  • Profitable 5 years in a row
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)23.7
Forward P/E27.9
P/FCF7.2
P/S0.4
P/B1.9
EV/EBITDA9.0
PEG—
Dividend yield4.02%
FCF yield13.8%
Shareholder yield7.3%
Intrinsic value vs. price−23%

Growth and quality

Revenue growth (1 yr)-20.1%
Revenue growth (5 yrs, per year)-3.7%
EPS growth (5 yrs, per year)-15.0%
FCF growth (3 yrs, per year)21.0%
Net margin (5-yr avg.)2.2%
ROIC (5-yr avg.)11.3%
Profitable years (of last 10)10
Years paying a dividend5

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$172M$183M$229M$200M$213M$206M$220M$233M$226M$203M$199M
Net income$3M$5M$10M$3M$3M$3M$13M$12M$7M$6M$2M
Free cash flow$9M$7M$11M$10M$4M$6M$13M$16M$15M$9M$6M
EPS (diluted)$0.21$0.40$0.75$0.23$0.20$0.24$0.90$0.79$0.50$0.41$0.11
Net margin1.6%2.8%4.3%1.5%1.2%1.5%5.9%5.0%3.3%2.8%0.8%
ROIC—11.7%21.1%7.4%5.7%10.7%24.0%35.4%27.6%22.7%11.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $6.50, 31% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.16 for the fiscal year ending June 30, 2027.

Frequently asked questions

What is Lifevantage’s P/E ratio?

About 23.7, based on the last twelve months of diluted earnings per share (forward P/E about 27.9).

Is Lifevantage stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 23% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Lifevantage pay a dividend?

Yes. The dividend yield is about 4.02%, and it has paid dividends for 5 years in our data.

Is Lifevantage a good stock to buy?

We do not give buy or sell advice. Lifevantage scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.